• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Once-Weekly Carfilzomib Improves PFS, OS in High-Risk Patients With MM Over Twice-Weekly Dose

Article

Patients with multiple myeloma (MM) who have high-risk cytogenetic abnormalities typically have shorter progression-free survival (PFS) and overall survival (OS) compared with standard-risk patients. In an analysis of 2 studies, patients with high-risk MM had improved outcomes when taking carfilzomib once a week compared with a twice-weekly dose.

Patients with multiple myeloma (MM) who have high-risk cytogenetic abnormalities typically have shorter progression-free survival (PFS) and overall survival (OS) compared with standard-risk patients, but carfilzomib (Kyprolis) has been demonstrated to improve survival in high-risk patients.

A study presented at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition investigated the role of carfilzomib, a second-generation protease inhibitor, in high-risk patients with newly diagnosed (ND) MM based on an analysis of 2 phase 1/2 studies. Patients were transplant ineligible and received nine 28-day induction cycles of carfilzomib, either 70 mg/m2 once weekly or 36 mg/m2 twice weekly, plus once weekly 300 mg/m2 cyclophosphamide and 40 mg dexamethasone.

A total of 121 NDMM patients were enrolled in the 2 studies and cytogenic data was available for 94 patients. Overall, 37 patients (31%) had high-risk chromosomal abnormalities: 18% had del(17p), 10% t(4;14), and 3% t(14;16).

After the induction phase, results were similar between the standard- and high-risk groups with an overall response rate of 86% and 92%, respectively, and near complete response of 39% and 41%, respectively.

However, after a median follow-up of 39 months, the median PFS was not reached in standard-risk patients and was 27.8 months in high-risk patients (hazard ratio: 0.76; P = .38). High-risk patients treated with once-weekly carfilzomib saw a greater PFS benefit with a median PFS of 39.6 months compared with a median PFS of 24.2 months for high-risk patients treated with twice-weekly carfilzomib.

In standard-risk patients, median OS was not reached during the follow-up period, and median OS was 47.5 months in high-risk patients. Again, patients taking the once-weekly dose saw improved outcomes. Median OS for high-risk patients taking the once-weekly dose was 47.5 months compared with 47.5 months in high-risk patients receiving the twice-weekly dose.

“As compared to twice weekly carfilzomib at 36 mg/m2, once weekly carfilzomib, at the dose of 70 mg/m2, confirmed to be effective in high-risk patients,” the authors concluded. “These data support the use of carfilzomib for the treatment of high-risk NDMM patients.”

Reference

Mina R, Larocca A, Petrucci MT, et al. Long-term carfilzomib for high-risk patients with newly-diagnosed multiple myeloma: a pooled analysis of two phase 1/2 studies. Presented at 60th American Society of Hematology Annual Meeting & Exposition; December 2, 2018. San Diego, CA. Abstract 3240.

Related Videos
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.